Literature DB >> 17313473

A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient.

R Walia1, J G Montoya, G S Visvesvera, G C Booton, R L Doyle.   

Abstract

Acanthamoeba species are known to cause 2 well-described entities: (1) granulomatous amoebic encephalitis (GAE), which usually affects immunocompromised hosts, and (2) keratitis, which typically follows trauma associated with contamination of water or contact lenses. Less common manifestations include pneumonitis and a subacute granulomatous dermatitis. We describe a case of granulomatous dermatitis secondary to Acanthamoeba infection in a lung transplant recipient and a successful outcome following treatment with lipid formulation of amphotericin B and voriconazole. We believe this is the second case report describing disseminated Acanthamoeba infection in a lung transplant recipient. We also describe successful outcome with a combination of lipid formulation of amphotericin B and voriconazole, drugs that have not been previously reported to treat Acanthamoeba.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17313473     DOI: 10.1111/j.1399-3062.2006.00159.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  20 in total

1.  Successful treatment of chronic stromal acanthamoeba keratitis with oral voriconazole monotherapy.

Authors:  Elmer Y Tu; Charlotte E Joslin; Megan E Shoff
Journal:  Cornea       Date:  2010-09       Impact factor: 2.651

Review 2.  Disseminated Acanthamoeba infection in a heart transplant recipient treated successfully with a miltefosine-containing regimen: Case report and review of the literature.

Authors:  Max N Brondfield; Michael J A Reid; Rachel L Rutishauser; Jennifer R Cope; Jevon Tang; Jana M Ritter; Almea Matanock; Ibne Ali; Sarah B Doernberg; Alexandra Hilts-Horeczko; Teresa DeMarco; Liviu Klein; Jennifer M Babik
Journal:  Transpl Infect Dis       Date:  2017-03-06       Impact factor: 2.228

Review 3.  The Development of Drugs against Acanthamoeba Infections.

Authors:  Ruqaiyyah Siddiqui; Yousuf Aqeel; Naveed Ahmed Khan
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 4.  Importance of nonenteric protozoan infections in immunocompromised people.

Authors:  J L N Barratt; J Harkness; D Marriott; J T Ellis; D Stark
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

5.  In vitro efficacy of corifungin against Acanthamoeba castellanii trophozoites and cysts.

Authors:  Anjan Debnath; Josefino B Tunac; Angélica Silva-Olivares; Silvia Galindo-Gómez; Mineko Shibayama; James H McKerrow
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

6.  Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba.

Authors:  C M Martín-Navarro; A López-Arencibia; F Arnalich-Montiel; B Valladares; J E Piñero; J Lorenzo-Morales
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-19       Impact factor: 3.117

7.  Voriconazole as a first-line treatment against potentially pathogenic Acanthamoeba strains from Peru.

Authors:  Alfonso Martín Cabello-Vílchez; Carmen M Martín-Navarro; Atteneri López-Arencibia; María Reyes-Batlle; Ines Sifaoui; Basilio Valladares; José E Piñero; Jacob Lorenzo-Morales
Journal:  Parasitol Res       Date:  2013-11-22       Impact factor: 2.289

8.  Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier.

Authors:  Duncan Webster; Imran Umar; Imram Umar; George Kolyvas; Juan Bilbao; Marie-Christine Guiot; Kevin Duplisea; Yvonne Qvarnstrom; Govinda S Visvesvara
Journal:  Am J Trop Med Hyg       Date:  2012-08-06       Impact factor: 2.345

9.  Evaluation of inhibitory potential of some selective methanolic plants extracts on biological characteristics of Acanthamoeba castellanii using human corneal epithelial cells in vitro.

Authors:  Hafiz Muhammad Shoaib; Ambreen Gul Muazzam; Asif Mir; Suk-Yul Jung; Abdul Matin
Journal:  Parasitol Res       Date:  2013-01-10       Impact factor: 2.289

Review 10.  CYP51 as drug targets for fungi and protozoan parasites: past, present and future.

Authors:  Galina I Lepesheva; Laura Friggeri; Michael R Waterman
Journal:  Parasitology       Date:  2018-04-12       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.